 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zhang Financial LLC grew its holdings in Tiziana Life Sciences Ltd (NASDAQ:TLSA  Free Report) by 61.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities...

Zhang Financial LLC Acquires 17,100 Shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA)

Tiziana Life Sciences initiates multi-center Phase 2a clinical trial of intranasal foralumab for na-SPMS...

Tiziana Life Sciences initiates multi-center Phase 2a clinical trial of intranasal foralumab for na-SPMS

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Tiziana Life Sciences initiates Phase 2a trial of intranasal foralumab

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ( Tiziana or the Company ), a biotechnology company developing breakthrough immunomodulation therapies via...

Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis

NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ( Tiziana or the Company ), a biotechnology company developing breakthrough immunomodulation therapies via...

Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Tiziana Life Sciences announces publication on intranasal foralumab

The authors conclude that nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer s disease (AD) FDA has cleared the IND for intranasal...

Study Validating MoA of Intranasal Foralumab in Alzheimer s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance

Tiziana Life Sciences highlights publication of promising Alzheimer s study results...

Tiziana Life Sciences highlights publication of promising Alzheimer s study results

Tiziana Life Sciences announces Foralumab presentation at ISNI meeting

NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ( Tiziana or the Company ), a biotechnology company developing breakthrough immunomodulation therapies via...

Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. It specializes in developing transformative therapies for neurodegenerative and lung diseases. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Watchers	2,989
52-Wk Low	$0.5005
52-Wk High	$1.39

Market Cap	$128.42M
Volume (M)	52,533.00
52-Wk High	$1.39
52-Wk Low	$0.5005

Current Price	$0.6599
Prev Close	$0.6708
Open	$0.67
Dividend Yield	0.00%
50-Day Moving Average	$0.6909
Beta	0.81
Avg. Volume	1.6M
PE Ratio	-4.28

52-Week High	$1.39
52-Week Low	$0.5005
Market Capitalization	$128.42M
EPS	-$0.1543
Price to Book	3.39
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-2.40

TLSA Tiziana Life Sciences Ltd

About

Feed

News

Sentiment

Earnings

Fundamentals